LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

Home・Akciju saraksts・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

4.78 -10.32

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.78

Max

5.33

Galvenie mērījumi
By Trading Economics
Ienākumi	-14M -14M
Pārdošana	-13M 6M
P/E Sektora vidējais	18.6 108.767
Peļņas marža	-238.621
Darbinieki	119
EBITDA	-13M -14M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+77.9% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	297M 945M
Iepriekšējā atvēršanas cena	15.1
Iepriekšējā slēgšanas cena	4.78

Ziņu noskaņojums

By Acuity

57%

43%

290 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

0.7658 / N/A Atbalsts un pretestība

CytomX Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. marts 18:43 UTC

Galvenie ziņu notikumi

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

2026. g. 3. marts 17:33 UTC

Iegādes, apvienošanās, pārņemšana

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

2026. g. 3. marts 23:45 UTC

Tirgus saruna

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

2026. g. 3. marts 23:44 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

2026. g. 3. marts 23:25 UTC

Tirgus saruna

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

2026. g. 3. marts 23:25 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 3. marts 22:38 UTC

Galvenie ziņu notikumi

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

2026. g. 3. marts 22:16 UTC

Peļņas

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

2026. g. 3. marts 22:09 UTC

Peļņas

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

2026. g. 3. marts 22:06 UTC

Peļņas

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

2026. g. 3. marts 22:05 UTC

Peļņas

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

2026. g. 3. marts 22:03 UTC

Peļņas

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

2026. g. 3. marts 21:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Tech, Media & Telecom Roundup: Market Talk

2026. g. 3. marts 21:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 3. marts 21:45 UTC

Galvenie ziņu notikumi

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

2026. g. 3. marts 21:37 UTC

Peļņas

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

2026. g. 3. marts 21:26 UTC

Galvenie ziņu notikumi

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

2026. g. 3. marts 20:31 UTC

Tirgus saruna

Galvenie ziņu notikumi

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

2026. g. 3. marts 20:04 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

2026. g. 3. marts 19:17 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold and Silver Drop as Energy Surges -- Market Talk

2026. g. 3. marts 18:43 UTC

Peļņas

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

2026. g. 3. marts 18:29 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Energy Roundup: Market Talk

2026. g. 3. marts 18:29 UTC

Tirgus saruna

Galvenie ziņu notikumi

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

2026. g. 3. marts 18:22 UTC

Galvenie ziņu notikumi

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

2026. g. 3. marts 18:22 UTC

Galvenie ziņu notikumi

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

2026. g. 3. marts 18:17 UTC

Tirgus saruna

Galvenie ziņu notikumi

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

2026. g. 3. marts 18:14 UTC

Peļņas

How Long Can Anthropic Play Defense? -- WSJ

2026. g. 3. marts 17:41 UTC

Galvenie ziņu notikumi

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

2026. g. 3. marts 17:36 UTC

Galvenie ziņu notikumi

Iran Conflict is Starting to Boost Gasoline Prices -- Update

2026. g. 3. marts 17:28 UTC

Iegādes, apvienošanās, pārņemšana

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Salīdzinājums

Cenas izmaiņa

CytomX Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

77.9% augšup

Prognoze 12 mēnešiem

Vidējais 9.5 USD 77.9%

Augstākais 10 USD

Zemākais 7 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

0.7658 / N/AAtbalsts un pretestība

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Noskaņojums

By Acuity

290 / 352 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.